- Home
- GCBC vs ERAS Comparison
GCBC vs ERAS Comparison
Compare GCBC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCBC
- ERAS
- Stock Information
- Founded
- GCBC 1889
- ERAS 2018
- Country
- GCBC United States
- ERAS United States
- Employees
- GCBC 209
- ERAS N/A
- Industry
- GCBC Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- GCBC Finance
- ERAS Health Care
- Exchange
- GCBC Nasdaq
- ERAS Nasdaq
- Market Cap
- GCBC 365.3M
- ERAS 348.4M
- IPO Year
- GCBC 1998
- ERAS 2021
- Fundamental
- Price
- GCBC $22.77
- ERAS $1.40
- Analyst Decision
- GCBC
- ERAS Strong Buy
- Analyst Count
- GCBC 0
- ERAS 6
- Target Price
- GCBC N/A
- ERAS $4.83
- AVG Volume (30 Days)
- GCBC 25.1K
- ERAS 1.7M
- Earning Date
- GCBC 07-22-2025
- ERAS 08-11-2025
- Dividend Yield
- GCBC 1.56%
- ERAS N/A
- EPS Growth
- GCBC 16.07
- ERAS N/A
- EPS
- GCBC 1.67
- ERAS N/A
- Revenue
- GCBC $69,414,000.00
- ERAS N/A
- Revenue This Year
- GCBC N/A
- ERAS N/A
- Revenue Next Year
- GCBC N/A
- ERAS N/A
- P/E Ratio
- GCBC $13.72
- ERAS N/A
- Revenue Growth
- GCBC 7.46
- ERAS N/A
- 52 Week Low
- GCBC $20.00
- ERAS $1.01
- 52 Week High
- GCBC $37.25
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- GCBC 55.24
- ERAS 49.66
- Support Level
- GCBC $21.60
- ERAS $1.31
- Resistance Level
- GCBC $23.13
- ERAS $1.49
- Average True Range (ATR)
- GCBC 0.64
- ERAS 0.11
- MACD
- GCBC 0.10
- ERAS -0.01
- Stochastic Oscillator
- GCBC 81.15
- ERAS 26.02
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.